AgingResearch.NewsJoin free

Iambic Therapeutics

CompanyUnited States

Iambic Therapeutics develops one asset, in phase 1 (IAM217 in ovarian cancer). Mostly small molecule acting on KIF18A; based in the United States.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1

  • IAM217

    Inhibits KIF18A to selectively disrupt mitotic spindle function in cancer cells

    Phase 1, Small molecule, KIF18A, ovarian cancer, triple-negative breast cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies6

Intelligence